Publications
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial +12012 | First Faculty of Medicine
- Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study2011 | First Faculty of Medicine
- Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy2010 | First Faculty of Medicine
- Autologous stem cell transplantation for AL amyloidosis –single-center results of a strict risk-adapted approach.2010 | First Faculty of Medicine
- Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre2010 | First Faculty of Medicine
- Results of autologous stem cell transplantation for AL amyloidosis in one Czech centerPublication without faculty affiliation
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Standardized 18F-FDG PET/CT in patients with myeloma: joint recommendation of Czech Myeloma Group and Czech Society of Nuclear Medicine2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Standardization of PET/CT in patients with multiple myeloma – Joint recommendation of The Czech Myeloma Group and The Czech Society of Nuclear Medicine2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...